Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Respiratory Syncytial Virus Infections 1Lymphoma, Follicular 1COVID-19 1Autoimmune Diseases 1

Interventions

telitacicept 3fludarabine 3Prednisone 3Data Collection 3Cyclophosphamide 3Specimen Handling 2Nivolumab 2Blood Specimen Collection 2Antilymphocyte Serum 2thymoglobulin 1remdesivir 1prednylidene 1human papillomavirus vaccine, L1 type 16, 18 1deltacortene 1carmustine, poliferprosan 20 drug combination 1cabozantinib 1apremilast 1Watchful Waiting 1Vitamin D 1Valsartan 1Telemedicine 1Surveys and Questionnaires 1Standard of Care 1Pyridostigmine Bromide 1Practice Guidelines as Topic 1Population Groups 1Platinum Compounds 1Plasma Exchange 1Phlebotomy 1Peripheral Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Autoimmune Diseases × remdesivir × Clear all
NCT06817889 2026-06-03

Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals

Fred Hutchinson Cancer Center

Phase 2 Recruiting
60 enrolled

Autoimmune Diseases, Respiratory Syncytial Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡